BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

443 related articles for article (PubMed ID: 15199446)

  • 1. Low-molecular-weight heparins for the treatment of acute coronary syndromes.
    Wong GC; Giugliano RP
    Semin Vasc Med; 2003 Nov; 3(4):391-402. PubMed ID: 15199446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of low-molecular-weight heparin in invasive management of non-ST-elevation acute coronary syndromes.
    Moser LR; Kalus JS
    Ann Pharmacother; 2004 Dec; 38(12):2094-104. PubMed ID: 15536140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved in-hospital outcomes in acute coronary syndromes (unstable angina/non-ST segment elevation myocardial infarction) despite similar TIMI risk scores.
    Almeda FQ; Hendel RC; Nathan S; Meyer PM; Calvin JE; Klein LW
    J Invasive Cardiol; 2003 Sep; 15(9):502-6. PubMed ID: 12947210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of low-molecular-weight heparins in non-ST-segment elevation acute coronary syndromes.
    Nguyen-Ho P; Levine GN
    Panminerva Med; 2002 Jun; 44(2):115-22. PubMed ID: 12032429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interactions between heparins, glycoprotein IIb/IIIa antagonists, and coronary intervention. The Global Registry of Acute Coronary Events (GRACE).
    Brieger D; Van de Werf F; Avezum A; Montalescot G; Kennelly BM; Granger CB; Goodman SG; Dabbous OH; Agnelli G;
    Am Heart J; 2007 Jun; 153(6):960-9. PubMed ID: 17540196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of low molecular weight heparins with antiplatelet agents in non-ST elevation acute coronary syndromes: an update.
    Cohen M
    Drugs; 2002; 62(12):1755-70. PubMed ID: 12149045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of low-molecular-weight heparin and glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
    Fernandez JS; Sadaniantz A
    Med Health R I; 2001 Feb; 84(2):37-43. PubMed ID: 11272658
    [No Abstract]   [Full Text] [Related]  

  • 8. Antithrombotic therapy and the transition to the catheterization laboratory in UA/NSTEMI.
    Ferguson JJ; Wilson JM; Diez J
    Minerva Cardioangiol; 2007 Oct; 55(5):529-56. PubMed ID: 17912162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of low-molecular-weight heparins in the management of acute coronary artery syndromes and percutaneous coronary intervention.
    Wong GC; Giugliano RP; Antman EM
    JAMA; 2003 Jan; 289(3):331-42. PubMed ID: 12525234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antithrombotic therapy in unstable angina/non-ST elevation myocardial infarction: the evolving role of low-molecular-weight heparin.
    Antman EM; Kereiakes DJ
    J Invasive Cardiol; 2000 Dec; 12 Suppl E():E1-4;discussion E25-8. PubMed ID: 11156721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-molecular-weight heparins and glycoprotein IIb/IIIa antagonists in acute coronary syndromes.
    Ferguson J
    J Invasive Cardiol; 2004 Mar; 16(3):136-44. PubMed ID: 15152164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute and prolonged treatment with low-molecular-weight heparin therapy in patients with unstable coronary artery disease.
    Husted S; Kher A
    Ann Med; 2000 Dec; 32 Suppl 1():53-9. PubMed ID: 11209983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unstable angina and non-ST-segment myocardial infarction: an evidence-based approach to management.
    Kou V; Nassisi D
    Mt Sinai J Med; 2006 Jan; 73(1):449-68. PubMed ID: 16470325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of low-molecular-weight heparins in the management of unstable angina and non-ST elevation myocardial infarction.
    Alwi I
    Acta Med Indones; 2008 Oct; 40(4):228-32. PubMed ID: 19530369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differences among low-molecular-weight heparins: evidence in patients with acute coronary syndromes.
    Nicolau JC; Cohen M; Montalescot G
    J Cardiovasc Pharmacol; 2009 Jun; 53(6):440-5. PubMed ID: 19365279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The present and future of heparin, low molecular weight heparins, pentasaccharide, and hirudin for venous thromboembolism and acute coronary syndromes.
    Haas S
    Semin Vasc Med; 2003 May; 3(2):139-46. PubMed ID: 15199477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [How to administer antithrombotic therapy in non-ST-elevation acute coronary syndromes: guidelines and clinical practice].
    Mafrici A
    Ital Heart J; 2005 May; 6 Suppl 3():24S-27S. PubMed ID: 15945316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of acute coronary syndromes with low molecular weight heparin: TIMI 11A and 11B.
    Turpie AG
    Can J Cardiol; 1998 Aug; 14 Suppl E():20E-23E. PubMed ID: 9779029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of antithrombotics for acute coronary syndromes in the emergency department: considerations and impact.
    Mukherjee D; Eagle KA
    Prog Cardiovasc Dis; 2007; 50(3):167-80. PubMed ID: 17976502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of un-fractionated heparin and low molecular weight heparin on hospital mortality in patients with non ST elevation acute coronary syndrome (ACS).
    Angkasuwapala K; Ratanasumawong K; Ngarmukos T; Kehasukcharoen W; Boonsom W; Kamsa-ard S
    J Med Assoc Thai; 2007 Oct; 90 Suppl 1():109-14. PubMed ID: 18431893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.